POLYNOVO LIMITED (PNV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PNV

PNV - POLYNOVO LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 2.19
Index: ASX300 | ALL-ORDS

PolyNovo is an Australian medical devices company developing and commercialising its NovoSorb technology for the treatment of burns, wounds and negative pressure wound therapy. It has been a listed company since 1998.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.345

27 Oct
2025

0.050

OPEN

$1.30

3.86%

HIGH

$1.36

2,896,346

LOW

$1.30

TARGET
$1.897 41.0% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
PNV: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 1.9 2.3 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx 100.0% 22.2% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 60.0 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx1.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx127.2 M
Book Value Per Share xxxxxxxxxxxxxxx12.1
Net Operating Cash Flow xxxxxxxxxxxxxxx3.9 M
Net Profit Margin xxxxxxxxxxxxxxx10.38 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx17.01 %
Return on Invested Capital xxxxxxxxxxxxxxx14.44 %
Return on Assets xxxxxxxxxxxxxxx11.11 %
Return on Equity xxxxxxxxxxxxxxx17.01 %
Return on Total Capital xxxxxxxxxxxxxxx4.77 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-10.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx15 M
Total Debt xxxxxxxxxxxxxxx17 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx34 M
Price To Book Value xxxxxxxxxxxxxxx9.92

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx13.9 M
Capex % of Sales xxxxxxxxxxxxxxx10.95 %
Cost of Goods Sold xxxxxxxxxxxxxxx82 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx40 M
Research & Development xxxxxxxxxxxxxxx8 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

26/08/2025

1

Buy

$2.00

48.70%

PolyNovo's total revenue of $127.3m in FY25 was in line with consensus, and EBITDA was at the bottom end of guidance.

Bell Potter notes sales growth was solid in FY25, recording double-digit growth and cash flow strengthened in 2H25. The outlook is promising with revenue in the US looking solid and non-US revenue now a meaningful contributor.

The broker reckons innovation pipeline remains central to long-term growth, with regulatory upgrade (PMA) expected in the December quarter a near-term catalyst.

Buy. Target unchanged at $2.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 3.30 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 3.80 cents.

Morgans

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

07/10/2025

1

Buy

$1.62

20.45%

Following Canaccord Genuity's acquisition of Wilsons, coverage of PolyNovo is transferred to Elyse Shapiro.

Buy. Target Price $1.62.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.00 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 3.40 cents.
Access Extra Coverage Research History >

PNV STOCK CHART

FNArena News on PNV

1
Australian Broker Call *Extra* Edition – Oct 07, 2025

Oct 07 2025 - Daily Market Reports
2
In Brief: NRW Holdings, Aroa Biosurgery, Online Retail Winners

Sep 12 2025 - Weekly Reports
3
In Case You Missed It – BC Extra Upgrades & Downgrades – 05-09-25

Sep 05 2025 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Sep 02, 2025

Sep 02 2025 - Daily Market Reports
5
FNArena Corporate Results Monitor – 26-08-2025

Aug 26 2025 - Australia

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
2
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
3
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
4
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
5
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
6
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
7
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
8
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
9
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
10
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps